# Individual Report — Pharma Vertical
# MindMap: Quantum ML Biomarker API for Clinical Trial Cohort Targeting

**Course:** Frontier Technologies — Future Strategic Opportunities  
**Programme:** IMBA 25J, IE Business School  
**Vertical:** Pharmaceutical Industry  
**Role in MindMap:** Validation Engine (H2 2026)

---

## The Problem: $3 Billion Per Drug, 90% Failure Rate

The pharmaceutical industry spends an average of **$3 billion per approved drug** (NIH/PMC, 2022). Approximately **90% of clinical trials fail** — not because the science is wrong, but because the wrong patients are recruited. The molecule often works. The problem is identifying, in advance, which patient population will respond.

The current standard approach to patient recruitment relies on:
- Historical clinical data and physician referrals
- Genetic biomarker screening (post-recruitment)
- Phase II/III failure as the discovery mechanism for poor cohort selection

By the time a trial fails due to cohort mismatch, $200–800 million has already been spent. The feedback loop is broken: the signal that would have predicted the failure existed before the trial began, but no one was reading it.

---

## The Missing Signal

Patients do not begin exhibiting symptoms in a clinical setting. They begin **searching**.

Before a patient with a neurological condition receives a diagnosis, they have typically spent months searching for:
- Symptom descriptions
- Differential diagnoses
- Treatment options
- Clinical trials
- Specialist referrals

This behavioral trajectory — the sequence and intensity of health-seeking searches in the months before diagnosis — is a measurable, population-level signal. It precedes clinical presentation. It is, in effect, a pre-clinical behavioral biomarker.

No pharma company currently reads this signal systematically. **MindMap's Quantum ML Biomarker API does.**

---

## The Solution: Quantum ML Biomarker API

The Quantum ML Biomarker API is a licensable classification engine that pharma companies integrate into their trial design and patient recruitment workflow.

### How It Works

**Step 1 — Signal Ingestion (Layer 1)**  
MindMap's behavioral data pipeline ingests population-level search signals indexed from Google Trends and supplementary sources across ICD-10 codes, PubMed literature, and licensed health data APIs.

**Step 2 — Behavioral Cohort Mapping (Layer 2)**  
Search signal clusters associated with specific condition trajectories are mapped to behavioral constructs: symptom onset patterns, health-seeking intensity, treatment research behaviour, and clinical trial awareness signals.

**Step 3 — Quantum ML Classification (Layer 3)**  
Google Willow's hybrid quantum-classical engine evaluates combinatorial interactions between behavioral signal dimensions. Classical ML finds correlations within predefined feature sets. The quantum engine evaluates how signals interact across the full combinatorial space — identifying non-obvious cohort characteristics that classical models miss.

**Step 4 — API Output**  
The API delivers:
- **Cohort probability scores:** Likelihood that a defined patient population will respond to the trial intervention, based on behavioral signal patterns
- **Recruitment targeting parameters:** Geographic and demographic signal concentrations indicating where the highest-response cohort is most densely distributed
- **Trial success probability:** Pre-trial forecast of Phase II/III success probability given current cohort composition

**Step 5 — Security Layer (Layer 4)**  
All outputs are delivered via post-quantum encrypted API endpoints. No individual patient data is ever processed — all signals are population-level aggregates. EU AI Act compliance is enforced at the output layer.

---

## Target Vertical: CNS and Life Sciences

### Why CNS First

Central Nervous System (CNS) conditions — Alzheimer's, Parkinson's, major depressive disorder, treatment-resistant depression, multiple sclerosis — represent the highest trial failure rate of any therapeutic area:

- CNS trial failure rate: **>90%** at Phase II/III
- Primary failure cause: Wrong patient population recruited
- Behavioral signal richness: Exceptionally high — CNS patients are prolific health-seekers with long pre-diagnosis behavioral trajectories
- Google Trends signal density: Neurological and mental health search terms are among the highest-volume sustained health search categories globally

CNS is where the behavioral signal is strongest and the failure cost is highest. It is the natural first beachhead.

### Target Partners

| Company | Relevance |
|---|---|
| Roche | Major CNS pipeline; Phase II/III failures documented publicly |
| Biogen | Alzheimer's and MS focus; historically high cohort mismatch costs |
| J&J (Janssen) | CNS and neuroscience division; active trial programmes |
| Pfizer | Broad CNS pipeline post-COVID; behavioural signal intersection with Long COVID |
| CNS Biotech companies | Smaller biotechs with limited recruitment budgets — highest ROI from API |

---

## Market Opportunity

**Global clinical trials market:** $75 billion annually  
**Failed trial costs attributable to cohort mismatch:** Estimated 40–60% of Phase II/III failures (industry consensus)  
**Addressable value if cohort targeting improves by 20%:** $15–25 billion in avoided trial costs annually

**Competitive landscape:**
- **IQVIA.ai:** Serves large pharma only; classical ML on claims and EHR data; no behavioral signal layer; no quantum ML
- **Medidata (Dassault):** Trial operations platform; no behavioral prediction
- **Veeva:** CRM and data for pharma; no predictive cohort targeting
- **Komodo Health:** Claims-based patient finding; no forward-looking behavioral signals

No platform currently does what the Quantum ML Biomarker API does. The combination of population-level behavioral signals + quantum-ML classification + pre-clinical targeting does not exist in the market.

---

## Three Horizons Roadmap — Pharma Vertical

### H1 (Now – mid 2026): Proof of Concept
- Select 1–2 CNS biotech partners for 90-day pilot study
- Define specific trial cohort targeting use case (e.g., treatment-resistant depression)
- Run behavioral signal pipeline against historical trial data to validate retrospective cohort prediction
- Establish baseline accuracy metric vs. standard recruitment approach
- Goal: demonstrate that behavioral signals carry statistically significant predictive power for cohort identification

### H2 (2026 – 2027): Validation and First Revenue
- 3 pharma pilots running in parallel (CNS focus)
- First prospective cohort targeting study underway (signal-guided recruitment into a live trial)
- Publish results (with partner consent) to establish scientific credibility
- API productised and priced (per-query or per-trial licence model)
- First revenue from API licensing
- Science validation unlocks insurance vertical trust (Insurance sees pharma proof; model credibility grows)

### H3 (2028 – 2030): Scale
- Pharma proof published publicly — scientific community validates the approach
- Expand beyond CNS to oncology, rare diseases, metabolic conditions
- API becomes standard pre-trial planning tool for mid-size and large pharma
- Data flywheel: every trial adds outcome data that improves the model
- 2030: MindMap is the behavioral intelligence standard for clinical trial cohort targeting

---

## The Predator Analogy

Every year, pharma companies spend $45–60 billion on trials that fail. Most of that failure was predictable. The signal existed. The population of people who would respond — or not respond — was already searching, already exhibiting behavioral patterns that mapped to their underlying condition trajectory.

The industry was not reading those signals because it did not have the tool to do so.

> *"The patients who will fail your trial are already telling you they will. They just aren't using clinical language. MindMap translates the signal."*

---

## Implementation Challenges and Honest Answers

**Challenge 1: Evidence bar is high**  
Pharma requires peer-reviewed validation before adopting a new recruitment tool. The H1 retrospective study addresses this directly — validating the model against known trial outcomes before any prospective use.

**Challenge 2: Data access**  
The API relies on population-level signals, not individual patient data. This removes the primary regulatory barrier. No patient consent is required for aggregate signal analysis.

**Challenge 3: Integration with existing workflows**  
The API is designed as a plug-in to existing trial design tools (e.g., Medidata, Veeva), not a replacement. Pharma companies add the behavioral targeting layer on top of their current stack.

**Challenge 4: Quantum hardware timeline**  
Full quantum processing for large-scale trial modelling is H2/H3. H1 uses quantum-inspired algorithms on classical hardware, which already outperform standard ML for the combinatorial cohort classification problem.

---

## How This Differs from the Group Presentation

The group presentation presents MindMap as a three-vertical platform with Insurance as the commercial anchor. This individual report focuses specifically on the Pharma vertical's role as the **Validation Engine** — the component that proves the science publicly, unlocks cross-vertical credibility, and creates the data flywheel that makes the full platform defensible at scale.

The group deck shows the platform. This report shows how the Quantum ML Biomarker API specifically works, why CNS is the right entry point, and what the H1-H3 evidence pathway looks like for pharma.
